ASCO 2022

Welcome to our ASCO 2022 landing page. Here you can find out more about our events planned at ASCO, the Elsevier’s Oncology Journal Network, and browse our special conference article collection.

Editor Meet and Greets at ASCO

Article collection

1. Can financial incentives encourage women to participate in a cervical cancer screening programme? Evidence from a randomized controlled trial analysis(opens in new tab/window), Journal of Cancer Policy

2. Low-value care and excess out-of-pocket expenditure among older adults with incident cancer – A machine learning approach(opens in new tab/window), Journal of Cancer Policy

3. Association between COVID-19 burden and delays to diagnosis and treatment of cancer patients in England(opens in new tab/window), Journal of Cancer Policy

4. Feasibility, usability and acceptance of weekly electronic patient-reported outcomes among patients receiving pelvic CT- or online MR-guided radiotherapy – A prospective pilot study(opens in new tab/window), Technical Innovations & Patient Support in Radiation Oncology

5. Acceptance of physical activity monitoring in cancer patients during radiotherapy, the GIROfit phase 2 pilot trial(opens in new tab/window), Technical Innovations & Patient Support in Radiation Oncology

6. Neurocognitive functioning following lung cancer treatment: The PRO-Long Study(opens in new tab/window), Technical Innovations & Patient Support in Radiation Oncology

7. Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations(opens in new tab/window), Cancer Treatment Reviews

8. Turning tumors from cold to inflamed to improve immunotherapy response(opens in new tab/window), Cancer Treatment Reviews

9. Clinical development of IDH1 inhibitors for cancer therapy(opens in new tab/window), Cancer Treatment Reviews

10. The association of polypharmacy with functional status impairments, frailty, and health-related quality of life in older adults with gastrointestinal malignancy - Results from the Cancer and Aging Resilience Evaluation (CARE) registry(opens in new tab/window), Journal of Geriatric Oncology

11. Feasibility and reliability of a self-administered geriatric assessment tool for Spanish-speaking Mexican older adults with cancer(opens in new tab/window), Journal of Geriatric Oncology

12. Association between chemotherapy toxicity risk scores and physical symptoms among older Brazilian adults with cancer(opens in new tab/window), Journal of Geriatric Oncology

13. Disparities in cancer screenings for sexual and gender minorities(opens in new tab/window), Current Problems in Cancer

14. Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib(opens in new tab/window), Current Problems in Cancer

15. HPV, vaccines, and cervical cancer in a low- and middle-income country(opens in new tab/window), Current Problems in Cancer

16. The perplexing role of immuno-oncology drugs in osteosarcoma(opens in new tab/window), Journal of Bone Oncology

17. In vitro three-dimensional cell cultures for bone sarcomas(opens in new tab/window), Journal of Bone Oncology

18. One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma(opens in new tab/window), Journal of Bone Oncology

19. Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1(opens in new tab/window), Transplantation and Cellular Therapy

20. Immune Reconstitution Following TCRαβ/CD19-Depleted Hematopoietic Cell Transplantation for Hematologic Malignancy in Pediatric Patients(opens in new tab/window), Transplantation and Cellular Therapy

21. Patient-Reported Outcomes for Cancer Patients with Hematological Malignancies Undergoing Chimeric Antigen Receptor T Cell Therapy: A Systematic Review(opens in new tab/window), Transplantation and Cellular Therapy

22. Combination therapy: Future directions of immunotherapy in small cell lung cancer(opens in new tab/window), Translational Oncology

23. Global colorectal cancer burden in 2020 and projections to 2040(opens in new tab/window), Translational Oncology

24. Early lung cancer diagnostic biomarker discovery by machine learning methods(opens in new tab/window), Translational Oncology

25. Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis(opens in new tab/window), Cancer Treatment and Research Communications

26. Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience(opens in new tab/window), Cancer Treatment and Research Communications

27. Chemotherapy-induced early transient increase and surge of CA 19–9 level in patients with pancreatic Adenocarcinoma(opens in new tab/window), Cancer Treatment and Research Communications

28. Biomarkers in Locally Advanced Rectal Cancer: A Review(opens in new tab/window), Clinical Colorectal Cancer

29. The Potential for Overtreatment With Total Neoadjuvant Therapy (TNT): Consider One Local Therapy Instead(opens in new tab/window), Clinical Colorectal Cancer

30. The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer(opens in new tab/window), Clinical Colorectal Cancer

31. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial(opens in new tab/window), Clinical Breast Cancer

32. The Role of Immune Cells in Breast Tissue and Immunotherapy for the Treatment of Breast Cancer(opens in new tab/window), Clinical Breast Cancer

33. Beta-2 Adrenergic Receptor Gene Expression in HER2-Positive Early-Stage Breast Cancer Patients: A Post-hoc Analysis of the NCCTG-N9831 (Alliance) Trial(opens in new tab/window), Clinical Breast Cancer

34. Locoregional treatment in oligometastatic breast cancer: A case report and review of treatment approaches in the era of cyclin inhibitors(opens in new tab/window), Current Problems in Cancer: Case Reports

35. Combination of osimertinib and pembrolizumab successfully overcome dual resistances in a patient with advanced adenocarcinoma of the lung, a case report(opens in new tab/window), Current Problems in Cancer: Case Reports

36. Pancreatic metastasis from malignant pleural mesothelioma. An extremely rare site of metastasis in a patient with a very prolonged survival of seven years(opens in new tab/window), Current Problems in Cancer: Case Reports

37. Postmastectomy radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. A 30-year long-term report from the Danish breast cancer cooperative group DBCG(opens in new tab/window), 82bc trial Radiotherapy & Oncology

38. Current practice in proton therapy delivery in adult cancer patients across Europe(opens in new tab/window), Radiotherapy & Oncology

39. The tubarial salivary glands: A potential new organ at risk for radiotherapy(opens in new tab/window), Radiotherapy & Oncology

40. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group(opens in new tab/window), Radiotherapy & Oncology

41. Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results(opens in new tab/window), Radiotherapy & Oncology

42. Association of genetic polymorphisms with psychological symptoms in cancer: A systematic review(opens in new tab/window), Asia-Pacific Journal of Oncology Nursing

43. Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy(opens in new tab/window), Asia-Pacific Journal of Oncology Nursing

44. Barriers in Nursing Practice in Cancer Cachexia: A Scoping Review(opens in new tab/window), Asia-Pacific Journal of Oncology Nursing

45. The Oncology Clinical Research Nurse Study Co-Ordinator: Past, Present, and Future(opens in new tab/window), Asia-Pacific Journal of Oncology Nursing

46. Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer(opens in new tab/window), Lung Cancer

47. Targeting KRAS G12C mutation in lung adenocarcinoma(opens in new tab/window), Lung Cancer

48. Immunotherapy for mesothelioma: Moving beyond single immune check point inhibition(opens in new tab/window), Lung Cancer

49. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy(opens in new tab/window), Lung Cancer

50. Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications(opens in new tab/window), Lung Cancer

51. 4D-MRI driven MR-guided online adaptive radiotherapy for abdominal stereotactic body radiation therapy on a high field MR-Linac: Implementation and initial clinical experience(opens in new tab/window), Clinical and Translational Radiation Oncology

52. Daily adaptive radiotherapy for patients with prostate cancer using a high field MR-linac: Initial clinical experiences and assessment of delivered doses compared to a C-arm linac(opens in new tab/window), Clinical and Translational Radiation Oncology

53. Selection criteria for early breast cancer patients in the DBCG proton trial – The randomised phase III trial strategy(opens in new tab/window), Clinical and Translational Radiation Oncology

54. COVID-19: Global radiation oncology's targeted response for pandemic preparedness(opens in new tab/window), Clinical and Translational Radiation Oncology

55. Adaptive radiotherapy: The Elekta Unity MR-linac concept(opens in new tab/window), Clinical and Translational Radiation Oncology

56. From 25 Fractions to Five: How Hypofractionation has Revolutionised Adjuvant Breast Radiotherapy(opens in new tab/window), Clinical Oncology

57. A Dose of Reality: Embracing the Unseen to Improve Stereotactic Radiotherapy(opens in new tab/window), Clinical Oncology

58. Single-Fraction Stereotactic Ablative Body Radiotherapy to the Lung – The Knockout Punch(opens in new tab/window), Clinical Oncology

59. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer(opens in new tab/window), Annals of Oncology

60. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies(opens in new tab/window), Annals of Oncology

61. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial(opens in new tab/window), Annals of Oncology

62. New Pro and Con discussion: Anthracyclines in the treatment of patients with early breast cancer(opens in new tab/window), ESMO Open

63. A qualitative study on the challenges health care professionals face when caring for adolescents and young adults with an uncertain and/or poor cancer prognosis(opens in new tab/window), ESMO Open

64. Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study(opens in new tab/window), ESMO Open

65. Multimodal predictors for precision immunotherapy(opens in new tab/window), Immuno-Oncology and Technology

66. CD47eSIRPa-targeted therapeutics: status and prospects(opens in new tab/window), Immuno-Oncology and Technology

67. Quantitative RNA assessment and long-term stability in the FFPE tumor samples using Digital Spatial Profiler(opens in new tab/window), Immuno-Oncology and Technology

68. A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer(opens in new tab/window), Critical Reviews in Oncology/Hematology

69. How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic review(opens in new tab/window), Critical Reviews in Oncology/Hematology

70. Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study(opens in new tab/window), Critical Reviews in Oncology/Hematology

71. The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis(opens in new tab/window), The Breast

72. Adjuvant endocrine therapy for premenopausal women with breast cancer: Patient adherence and physician prescribing practices in Mexico(opens in new tab/window), The Breast

73. Impact of body mass index on overall survival in patients with metastatic breast cancer(opens in new tab/window), The Breast

74. Outcome beyond third-line chemotherapy for metastatic triple-negative breast cancer in the French ESME program(opens in new tab/window), The Breast

75. Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blasts(opens in new tab/window), Leukemia Research

76. A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia(opens in new tab/window), Leukemia Research

77. Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS(opens in new tab/window), Leukemia Research

78. CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies(opens in new tab/window), Leukemia Research Reports

79. Role of antibody-based therapy in indolent non-Hodgkin's lymphoma(opens in new tab/window), Leukemia Research Reports

80. Acute myeloid leukemia with RAM immunophenotype presenting with extensive mesenteric and retroperitoneal lymphadenopathy: A case report and review of the literature(opens in new tab/window), Leukemia Research Reports

81. Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non–Small Cell Lung Cancer: Results From a Phase 1b Trial(opens in new tab/window), Clinical Lung Cancer

82. The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients(opens in new tab/window), Clinical Lung Cancer

83. Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review(opens in new tab/window), Clinical Lung Cancer

84. Identification and Validation of the Prognostic Impact of Metastatic Prostate Cancer Phenotypes(opens in new tab/window), Clinical Genitourinary Cancer

85. Segmental Ureterectomy Versus Radical Nephroureterectomy in Older Patients Treated for Upper Tract Urothelial Carcinoma(opens in new tab/window), Clinical Genitourinary Cancer

86. Impact of New Systemic Therapies in Overall Survival in Non-Metastatic Castration Resistant Prostate Cancer: Systematic Review and Meta-Analysis(opens in new tab/window), Clinical Genitourinary Cancer

87. Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma(opens in new tab/window), Clinical Lymphoma Myeloma and Leukemia

88. Outcomes of HTLV-1 Carriers with Diffuse Large B-Cell Lymphoma: A Single-Center Retrospective Matched Cohort Study(opens in new tab/window), Clinical Lymphoma Myeloma and Leukemia

89. Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies(opens in new tab/window), Clinical Lymphoma Myeloma and Leukemia

90. Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer(opens in new tab/window), Gynecologic Oncology

91. Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer(opens in new tab/window), Gynecologic Oncology

92. Surgical outcomes of diaphragmatic resection during cytoreductive surgery for advanced gynecological ovarian neoplasia: A randomized single center clinical trial – DRAGON. (opens in new tab/window)Gynecologic Oncology

93. Lessons learned: Telemedicine patterns and clinical application in patients with gynecologic cancers during COVID-19(opens in new tab/window), Gynecologic Oncology Reports

94. Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutation(opens in new tab/window), Gynecologic Oncology Reports

95. Retrospective analysis of bevacizumab-induced arthralgia and clinical outcomes in ovarian cancer patients. Single center experience(opens in new tab/window), Gynecologic Oncology Reports

96. Oncologic outcomes of pathologic T4 and T3 colon cancer patients diagnosed with clinical T4 stage disease using preoperative computed tomography scan(opens in new tab/window), Surgical Oncology

97. Multidisciplinary management of early rectal cancer – The role of surgical local excision in current and future clinical practice(opens in new tab/window), Surgical Oncology

98. Pancreaticoduodenectomy in octogenarians: The importance of “biological age” on clinical outcomes(opens in new tab/window), Surgical Oncology

99. Quitting Smoking At or Around Diagnosis Improves the Overall Survival of Lung Cancer Patients: A Systematic Review and Meta-Analysis(opens in new tab/window), Journal of Thoracic Oncology

100. International Association for the Study of Lung Cancer Study of the Impact of Coronavirus Disease 2019 on International Lung Cancer Clinical Trials(opens in new tab/window), Journal of Thoracic Oncology

101. Patient Adherence to Lung CT Screening Reporting & Data System–Recommended Screening Intervals in the United States: A Systematic Review and Meta-Analysis(opens in new tab/window), Journal of Thoracic Oncology

102. The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers(opens in new tab/window), European Journal of Cancer

103. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing(opens in new tab/window), European Journal of Cancer

104. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer(opens in new tab/window), European Journal of Cancer

105. Therapeutic vaccines for breast cancer: Has the time finally come?(opens in new tab/window)European Journal of Cancer

106. Adjuvant treatment for melanoma in clinical practice – Trial versus reality(opens in new tab/window), European Journal of Cancer

Oncology journal network

We’ll help you find the right home for your research – fast

Publishing your work can be time-consuming, especially if the first journal you submit to isn’t right for your research. With over 40 journals, including The Lancet Oncology, Cancer Cell, European Journal of Cancer and Cancer Letters, Elsevier’s Oncology Journal Network has the right home for your research. And with our transfer service, you’ll benefit from a smooth, simple publishing process.